Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient.
Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.
Early Years and Foundation
Starpharma was founded in 1996 as a spin-off company from CSIRO to leverage the potential of dendrimers, synthetic nanoscale polymers. Starpharma was listed on the Australian Securities Exchange (ASX) in September 2000. Initially, our research focused on developing dendrimer-based products for antiviral applications, particularly HIV and other STIs, then later expanded into bacterial vaginosis (BV). Starpharma developed the DEP® (dendrimer enhanced product) drug delivery platform in the early 2000s, shifting its strategy to centre on refining the dendrimer technology to enhance drug delivery, focusing on oncology.
Key Developments and Milestones
Starpharma has made significant strides in advancing dendrimer-based products through preclinical and clinical trials. The Company has collaborated with international pharmaceutical and biotechnology companies to explore applications of dendrimers in drug delivery and other medical fields. Starpharma achieved significant milestones with the commercialisation of its anti-infective products, VivaGel® BV, VivaGel® Condom, and VIRALEZE™ Nasal Spray, which gained market approval and launched in several countries.
In recent years, Starpharma has generated extensive clinical validation of the DEP® platform technology through the clinical development of multiple DEP® candidates. More than 350 patients have been treated with the DEP® technology across multiple clinical programs, generating valuable data. Starpharma has also continued to innovate in dendrimer technology, expanding its applications into novel diagnostic and therapeutic areas.
Corporate Vision and Future Directions
Starpharma has a long history of forming partnerships and developing assets, laying a strong foundation for driving growth and delivering returns to shareholders. Looking forward, Starpharma aims to strengthen its position as a leader in dendrimer technology. The Company is focused on advancing its pipeline of products through continued research and development, aiming to address unmet medical needs and explore new commercial opportunities globally. Starpharma's journey reflects its commitment to innovation in dendrimer-based technologies, positioning itself at the forefront of biotechnology advancements in Australia.
